Literature DB >> 33441429

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.

Marcos V P Gondim1, Scott Sherrill-Mix1,2, Frederic Bibollet-Ruche1,2, Ronnie M Russell1,2, Stephanie Trimboli3, Andrew G Smith4, Yingying Li1, Weimin Liu1, Alexa N Avitto5, Julia C DeVoto6, Jesse Connell1,2, Angharad E Fenton-May7, Pierre Pellegrino8, Ian Williams8, Emmanouil Papasavvas9, Julio C C Lorenzi10, D Brenda Salantes11, Felicity Mampe1, M Alexandra Monroy1, Yehuda Z Cohen12, Sonya Heath13, Michael S Saag13, Luis J Montaner9, Ronald G Collman1,2, Janet M Siliciano14, Robert F Siliciano14,15, Lindsey J Plenderleith16,17, Paul M Sharp16,17, Marina Caskey10, Michel C Nussenzweig10,18, George M Shaw1,2, Persephone Borrow7, Katharine J Bar1,2, Beatrice H Hahn19,2.   

Abstract

Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission. However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an incomplete understanding of their antiviral activities at later stages of infection. Here, we characterized the IFN-I sensitivity of 500 clonally derived HIV-1 isolates from the plasma and CD4+ T cells of 26 individuals sampled longitudinally after transmission or after antiretroviral therapy (ART) and analytical treatment interruption. We determined the concentration of IFNα2 and IFNβ that reduced viral replication in vitro by 50% (IC50) and found consistent changes in the sensitivity of HIV-1 to IFN-I inhibition both across individuals and over time. Resistance of HIV-1 isolates to IFN-I was uniformly high during acute infection, decreased in all individuals in the first year after infection, was reacquired concomitant with CD4+ T cell loss, and remained elevated in individuals with accelerated disease. HIV-1 isolates obtained by viral outgrowth during suppressive ART were relatively IFN-I sensitive, resembling viruses circulating just before ART initiation. However, viruses that rebounded after treatment interruption displayed the highest degree of IFNα2 and IFNβ resistance observed at any time during the infection course. These findings indicate a dynamic interplay between host innate responses and the evolving HIV-1 quasispecies, with the relative contribution of IFN-I to HIV-1 control affected by both ART and analytical treatment interruption. Although elevated at transmission, host innate pressures are the highest during viral rebound, limiting the viruses that successfully become reactivated from latency to those that are IFN-I resistant.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33441429      PMCID: PMC7923595          DOI: 10.1126/scitranslmed.abd8179

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  86 in total

1.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

Review 2.  Generalized immune activation and innate immune responses in simian immunodeficiency virus infection.

Authors:  Steven E Bosinger; Donald L Sodora; Guido Silvestri
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

Review 3.  Innate immunity in acute HIV-1 infection.

Authors:  Persephone Borrow
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

4.  Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial.

Authors:  François Boué; Jacques Reynes; Christine Rouzioux; Dominique Emilie; Faouzi Souala; Rolland Tubiana; Cécile Goujard; Rémi Lancar; Dominique Costagliola
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

Review 5.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

6.  Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression.

Authors:  M S Künzi; H Farzadegan; J B Margolick; D Vlahov; P M Pitha
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

Review 7.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728

Review 8.  Interferons, interferon-like cytokines, and their receptors.

Authors:  Sidney Pestka; Christopher D Krause; Mark R Walter
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

Review 9.  CD8+ T cells in HIV control, cure and prevention.

Authors:  David R Collins; Gaurav D Gaiha; Bruce D Walker
Journal:  Nat Rev Immunol       Date:  2020-02-12       Impact factor: 53.106

10.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Authors:  Angharad E Fenton-May; Oliver Dibben; Tanja Emmerich; Haitao Ding; Katja Pfafferott; Marlen M Aasa-Chapman; Pierre Pellegrino; Ian Williams; Myron S Cohen; Feng Gao; George M Shaw; Beatrice H Hahn; Christina Ochsenbauer; John C Kappes; Persephone Borrow
Journal:  Retrovirology       Date:  2013-12-03       Impact factor: 4.602

View more
  13 in total

Review 1.  An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection.

Authors:  Mathias Lichterfeld; Ce Gao; Xu G Yu
Journal:  Trends Immunol       Date:  2022-08       Impact factor: 19.709

Review 2.  HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies.

Authors:  Edward F Kreider; Katharine J Bar
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-11       Impact factor: 5.495

Review 3.  Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies.

Authors:  Tram M Ta; Sajjaf Malik; Elizabeth M Anderson; Amber D Jones; Jocelyn Perchik; Maryann Freylikh; Luca Sardo; Zackary A Klase; Taisuke Izumi
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 6.064

4.  Differential Inhibition of HIV Replication by the 12 Interferon Alpha Subtypes.

Authors:  Armando Espinosa Ortiz; Olivia Blake; Alexandra Tauzin; Calaiselvy Soundaramourty; Charles Joly-Beauparlant; Alexandre Nicolas; Arnaud Droit; Jacques Dutrieux; Jérôme Estaquier; Fabrizio Mammano
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

5.  Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.

Authors:  P Zacharopoulou; E Marchi; A Ogbe; N Robinson; H Brown; M Jones; L Parolini; M Pace; N Grayson; P Kaleebu; H Rees; S Fidler; P Goulder; P Klenerman; J Frater
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.996

Review 6.  The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence.

Authors:  Yang-Hui Jimmy Yeh; Kerui Yang; Anya Razmi; Ya-Chi Ho
Journal:  Viruses       Date:  2021-09-17       Impact factor: 5.818

7.  A point mutation in HIV-1 integrase redirects proviral integration into centromeric repeats.

Authors:  Shelby Winans; Hyun Jae Yu; Kenia de Los Santos; Gary Z Wang; Vineet N KewalRamani; Stephen P Goff
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

Review 8.  HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection.

Authors:  Silvere D Zaongo; Jing Ouyang; Yaling Chen; Yan-Mei Jiao; Hao Wu; Yaokai Chen
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

9.  Evolution of enhanced innate immune evasion by SARS-CoV-2.

Authors:  Lucy G Thorne; Mehdi Bouhaddou; Ann-Kathrin Reuschl; Lorena Zuliani-Alvarez; Ben Polacco; Adrian Pelin; Jyoti Batra; Matthew V X Whelan; Myra Hosmillo; Andrea Fossati; Roberta Ragazzini; Irwin Jungreis; Manisha Ummadi; Ajda Rojc; Jane Turner; Marie L Bischof; Kirsten Obernier; Hannes Braberg; Margaret Soucheray; Alicia Richards; Kuei-Ho Chen; Bhavya Harjai; Danish Memon; Joseph Hiatt; Romel Rosales; Briana L McGovern; Aminu Jahun; Jacqueline M Fabius; Kris White; Ian G Goodfellow; Yasu Takeuchi; Paola Bonfanti; Kevan Shokat; Natalia Jura; Klim Verba; Mahdad Noursadeghi; Pedro Beltrao; Manolis Kellis; Danielle L Swaney; Adolfo García-Sastre; Clare Jolly; Greg J Towers; Nevan J Krogan
Journal:  Nature       Date:  2021-12-23       Impact factor: 69.504

10.  Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant.

Authors:  Lucy G Thorne; Mehdi Bouhaddou; Ann-Kathrin Reuschl; Lorena Zuliani-Alvarez; Ben Polacco; Adrian Pelin; Jyoti Batra; Matthew V X Whelan; Manisha Ummadi; Ajda Rojc; Jane Turner; Kirsten Obernier; Hannes Braberg; Margaret Soucheray; Alicia Richards; Kuei-Ho Chen; Bhavya Harjai; Danish Memon; Myra Hosmillo; Joseph Hiatt; Aminu Jahun; Ian G Goodfellow; Jacqueline M Fabius; Kevan Shokat; Natalia Jura; Klim Verba; Mahdad Noursadeghi; Pedro Beltrao; Danielle L Swaney; Adolfo Garcia-Sastre; Clare Jolly; Greg J Towers; Nevan J Krogan
Journal:  bioRxiv       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.